Welcome to our dedicated page for Structure Therapeutics news (Ticker: GPCR), a resource for investors and traders seeking the latest updates and insights on Structure Therapeutics stock.
Structure Therapeutics Inc. develops oral small-molecule therapeutics for chronic metabolic diseases, with a focus on obesity. The clinical-stage global biopharmaceutical company uses a structure-based drug discovery platform and GPCR-targeted pipeline to advance wholly owned compounds, including aleniglipron, an oral nonpeptide GLP-1 receptor agonist, and ACCG-2671, an oral amylin receptor agonist.
Recurring company updates include clinical data from the ACCESS aleniglipron program, obesity and weight-management research presentations, financial results, research-and-development funding, ADS and warrant financings, and leadership or governance changes. The company’s American depositary shares trade under GPCR, with each ADS representing three ordinary shares.
Summary not available.
Structure Therapeutics Inc. (NASDAQ: GPCR) reported its financial results for Q4 2022 and the full year ended December 31, 2022. The company completed its upsized IPO, raising approximately $185.3 million, with net proceeds of around $166.7 million. This funding bolsters its efforts to develop GSBR-1290, an oral GLP-1 agonist for type 2 diabetes and obesity. The Phase 1b study is now completed, and the firm anticipates topline data from the upcoming Phase 1b and Phase 2a studies in the second half of 2023. The net loss for 2022 was $51.3 million, a significant increase from $38.0 million in 2021, primarily due to heightened R&D expenses.
Structure Therapeutics Inc. (NASDAQ: GPCR) has successfully closed its upsized initial public offering (IPO) of 12,351,000 American depositary shares (ADSs) at a price of $15.00 per ADS, generating approximately $185.3 million before expenses. This offering included the full exercise of underwriters' options to purchase an additional 1,611,000 ADSs. The shares commenced trading on Nasdaq on February 3, 2023. Jefferies, SVB Securities, Guggenheim Securities, and BMO Capital Markets served as joint book-running managers for the offering. Structure Therapeutics focuses on developing novel oral small molecule therapeutics for metabolic and pulmonary diseases targeting the GPCR family.
Structure Therapeutics Inc. (NASDAQ: GPCR), backed by Qiming Venture Partners, successfully debuted on Nasdaq on February 3, 2023. Issued at $15.00 per ADS, it opened at $25.00, marking a 66.67% increase and a market cap of $915 million. Qiming Venture Partners has been an early investor since 2019. Structure Therapeutics focuses on converting biologics into orally available small molecules, targeting G-protein-coupled receptors. Their pipeline includes GSBR-1290 for type-2 diabetes and ANPA-0073 for pulmonary conditions, with significant studies completed in September 2022.
Structure Therapeutics Inc. (NASDAQ: GPCR) has successfully priced its upsized initial public offering (IPO) of 10,740,000 American depositary shares (ADSs) at $15.00 per ADS, anticipating gross proceeds of approximately $161.1 million. The offering includes a 30-day option for underwriters to purchase an additional 1,611,000 ADSs. Trading on the Nasdaq Global Market is set to begin on February 3, 2023, with completion expected by February 7, 2023. Structure Therapeutics focuses on developing novel oral therapeutics for metabolic and pulmonary diseases, leveraging a structure-based drug discovery platform.